他免疫抑制剂他克莫司(TAC)在中重度溃疡性结肠炎(UC)患者的缓解诱导治疗中被使用，之前的队列研究显示了其短期疗效和相关预测因素。然而，大多数研究仅报告了单个中心招募的有限数量患者的数据。我们进行了一项大规模多中心回顾性队列研究，旨在确定UC患者口服TAC治疗期间与临床缓解预测相关的因素。回顾分析了2009年4月至2017年3月间在7个机构接受TAC作为缓解诱导的中重度UC患者的病历。共分析了216个接受诱导的患者，其中123人(56.9%)在第12周显示临床缓解。逻辑回归分析表明，之前或目前使用抗肿瘤坏死因子(TNF)-α抗体(比值比[OR]，0.259；P = .006)和基线时合并使用5-氨基水杨酸(5-ASA)（OR, 0.268；P = .005）是与临床缓解失败相关的独立预测因素，而更高的C-反应蛋白水平(OR, 1.124；P = .014)预测了临床缓解的实现。这项多中心研究的结果清楚地显示了TAC诱导治疗在中重度UC患者中的疗效。值得注意的是，之前或目前使用抗TNF-α抗体与第12周临床缓解的成就较差相关。© 作者 2023。由牛津大学出版社代表Crohn's & Colitis基金会出版。版权所有。如需权限，请发送电子邮件至: journals.permissions@oup.com。

Tacrolimus (TAC), a calcineurin inhibitor, is used for remission induction therapy in patients with moderate to severe ulcerative colitis (UC), with short-term efficacy and related predictive factors shown in previous cohort studies. However, most studies reported data for only a limited number of patients enrolled from a single center. We performed a large multicenter retrospective cohort study to identify factors related to prediction of clinical remission in UC patients treated with oral TAC.The medical records of patients with moderate to severe UC treated with oral TAC as induction therapy at 7 institutions between April 2009 and March 2017 were retrospectively reviewed.A total of 216 patients who received TAC for induction were analyzed, of whom 123 (56.9%) showed clinical remission at week 12. Logistic regression analysis indicated that previous or current use of antitumor necrosis factor (TNF)-α antibodies (odds ratio [OR], 0.259; P = .006), and concomitant treatment with 5-aminosalicylate (5-ASA) at the baseline (OR, 0.268; P = .005) were independent predictive factors correlated with failure of clinical remission, whereas higher levels of C-reactive protein (OR, 1.124; P = .014) predicted achievement of clinical remission.Results of this multicenter study clearly indicate the efficacy of TAC induction therapy for patients with moderate to severe UC. Notably, previous or current use of anti-TNF-α antibodies was associated with poor achievement of clinical remission by week 12.© The Author(s) 2023. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.